127 related articles for article (PubMed ID: 33125383)
21. Screening for prostate cancer decreases the risk of developing metastatic disease: findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC).
Schröder FH; Hugosson J; Carlsson S; Tammela T; Määttänen L; Auvinen A; Kwiatkowski M; Recker F; Roobol MJ
Eur Urol; 2012 Nov; 62(5):745-52. PubMed ID: 22704366
[TBL] [Abstract][Full Text] [Related]
22. Management of patients with high-risk and advanced prostate cancer in the Middle East: resource-stratified consensus recommendations.
Mukherji D; Youssef B; Dagher C; El-Hajj A; Nasr R; Geara F; Rabah D; Al Dousari S; Said R; Ashou R; Wazzan W; Jabbour M; Farha G; Al Hamdani N; Al Hallaq Y; Ghazal H; Dbouk H; Bachir B; El Khoury C; Sakr G; Hussain HK; Sayyid K; Ibrahim K; Haidar M; Zouain N; Bitar N; Alameh W; Abbas F; Faddoul S; Nemer E; Assaf G; Farhat F; Bulbul M; Temraz S; Shamseddine A; Gillessen S; Omlin A; Khauli R
World J Urol; 2020 Mar; 38(3):681-693. PubMed ID: 31297628
[TBL] [Abstract][Full Text] [Related]
23. The effect of a Rapid Access Prostate Cancer Clinic on prostate cancer patient and disease characteristics, primary treatment and surgical workload.
Oon SF; Cullen IM; Moran D; Bolton EM; McDermott T; Grainger R; Lynch TH
Ir J Med Sci; 2014 Jun; 183(2):241-7. PubMed ID: 23925926
[TBL] [Abstract][Full Text] [Related]
24. The Prostate Cancer Intervention Versus Observation Trial: VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy with watchful waiting for men with clinically localized prostate cancer.
Wilt TJ
J Natl Cancer Inst Monogr; 2012 Dec; 2012(45):184-90. PubMed ID: 23271771
[TBL] [Abstract][Full Text] [Related]
25. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial.
Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
Lancet Oncol; 2014 Sep; 15(10):1076-89. PubMed ID: 25130995
[TBL] [Abstract][Full Text] [Related]
26. Duration of androgen suppression before radiotherapy for localized prostate cancer: radiation therapy oncology group randomized clinical trial 9910.
Pisansky TM; Hunt D; Gomella LG; Amin MB; Balogh AG; Chinn DM; Seider MJ; Duclos M; Rosenthal SA; Bauman GS; Gore EM; Rotman MZ; Lukka HR; Shipley WU; Dignam JJ; Sandler HM
J Clin Oncol; 2015 Feb; 33(4):332-9. PubMed ID: 25534388
[TBL] [Abstract][Full Text] [Related]
27. Managing localized prostate cancer in the era of prostate-specific antigen screening.
Brooks JD
Cancer; 2013 Nov; 119(22):3906-9. PubMed ID: 24006273
[TBL] [Abstract][Full Text] [Related]
28. Cumulative probability of prostate cancer detection in biopsy according to free/total PSA ratio in men with total PSA levels of 2.1-10.0 ng/ml at population screening.
Kitagawa Y; Ueno S; Izumi K; Kadono Y; Konaka H; Mizokami A; Namiki M
J Cancer Res Clin Oncol; 2014 Jan; 140(1):53-9. PubMed ID: 24165867
[TBL] [Abstract][Full Text] [Related]
29. Opportunistic testing versus organized prostate-specific antigen screening: outcome after 18 years in the Göteborg randomized population-based prostate cancer screening trial.
Arnsrud Godtman R; Holmberg E; Lilja H; Stranne J; Hugosson J
Eur Urol; 2015 Sep; 68(3):354-60. PubMed ID: 25556937
[TBL] [Abstract][Full Text] [Related]
30. Could Differences in Treatment Between Trial Arms Explain the Reduction in Prostate Cancer Mortality in the European Randomized Study of Screening for Prostate Cancer?
Carlsson SV; Månsson M; Moss S; Kwiatkowski M; Recker F; Tammela TLJ; Bangma C; Roobol MJ; Auvinen A; Hugosson J
Eur Urol; 2019 Jun; 75(6):1015-1022. PubMed ID: 30928162
[TBL] [Abstract][Full Text] [Related]
31. PSA screening, prostate biopsy, and treatment of prostate cancer in the years surrounding the USPSTF recommendation against prostate cancer screening.
Kearns JT; Holt SK; Wright JL; Lin DW; Lange PH; Gore JL
Cancer; 2018 Jul; 124(13):2733-2739. PubMed ID: 29781117
[TBL] [Abstract][Full Text] [Related]
32. Factors Associated with Discontinuation of Active Surveillance among Men with Low-Risk Prostate Cancer: A Population-Based Study.
Timilshina N; Komisarenko M; Martin LJ; Cheung DC; Alibhai S; Richard PO; Finelli A
J Urol; 2021 Oct; 206(4):903-913. PubMed ID: 34412510
[TBL] [Abstract][Full Text] [Related]
33. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
34. Prostate cancer.
Castillejos-Molina RA; Gabilondo-Navarro FB
Salud Publica Mex; 2016 Apr; 58(2):279-84. PubMed ID: 27557386
[TBL] [Abstract][Full Text] [Related]
35. Long-term outcomes among noncuratively treated men according to prostate cancer risk category in a nationwide, population-based study.
Rider JR; Sandin F; Andrén O; Wiklund P; Hugosson J; Stattin P
Eur Urol; 2013 Jan; 63(1):88-96. PubMed ID: 22902040
[TBL] [Abstract][Full Text] [Related]
36. Expectant management of veterans with early-stage prostate cancer.
Filson CP; Shelton JB; Tan HJ; Kwan L; Skolarus TA; Saigal CS; Litwin MS
Cancer; 2016 Feb; 122(4):626-33. PubMed ID: 26540451
[TBL] [Abstract][Full Text] [Related]
37. Prostate cancer screening among elderly men in Brazil: should we diagnose or not?
Mori RR; Faria EF; Mauad EC; Rodrigues AA; Dos Reis RB
Int Braz J Urol; 2020; 46(1):34-41. PubMed ID: 31851456
[TBL] [Abstract][Full Text] [Related]
38. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial.
Boevé LMS; Hulshof MCCM; Vis AN; Zwinderman AH; Twisk JWR; Witjes WPJ; Delaere KPJ; Moorselaar RJAV; Verhagen PCMS; van Andel G
Eur Urol; 2019 Mar; 75(3):410-418. PubMed ID: 30266309
[TBL] [Abstract][Full Text] [Related]
39. Prostate cancer meeting the Japanese active surveillance criteria and diagnosed by community-based prostate-specific antigen screening: A 21-year follow-up study.
Hongo F; Okihara K; Kitamura K; Fujihara A; Yamada Y; Shiraishi T; Konishi E; Ukimura O
Int J Urol; 2019 Aug; 26(8):827-832. PubMed ID: 31183899
[TBL] [Abstract][Full Text] [Related]
40. Role of active surveillance and focal therapy in low- and intermediate-risk prostate cancers.
van der Poel H; Klotz L; Andriole G; Azzouzi AR; Bjartell A; Cussenot O; Hamdy F; Graefen M; Palma P; Rivera AR; Stief CG
World J Urol; 2015 Jul; 33(7):907-16. PubMed ID: 26037891
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
